uHeart, a 3D model of physiological human myocardium, is the ideal tool to screen drug cardiotoxicity as early as possible in the drug discovery pipeline. Validated in collaboration with Accelera Srl by testing 12 reference compounds, uHeart demonstrated a sensitivity of 83.3%, a specificity of 100% and an accuracy of 91.6% in detecting drug cardiotoxicity. BiomimX® offers services for screening biomolecules’ cardiotoxicity on uHeart model.
Check out our publication.